Royalty Pharma plc
-
Ticker
RPRX
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 11-50 Employees
- Based in New York City, New York
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of
…More royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates.
REPORT RATINGS
5.0 / 5.0 (1)
Royalty Pharma plc reports have an aggregate usefulness score of 5.0 based on 1 reviews.
Royalty Pharma plc
Most Recent Responsibility Report
MOST RECENT
2023 Corporate Responsibility Report
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Royalty Pharma plc Sustainability Report, Royalty Pharma plc Corporate Social Responsibility Report, Royalty Pharma plc CSR Report, Royalty Pharma plc Corporate Responsibility, Royalty Pharma plc CR Report, Royalty Pharma plc Citizenship Report, Royalty Pharma plc ESG Report, and Royalty Pharma plc Environmental Report online.